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1  | INTRODUC TION
The January 30, 2020, the World Health Organization (WHO) 
declared a global health emergency for an outbreak of a novel 
Coronavirus (SARS-CoV-2) that occurred in the city of Wuhan (Hubei 
province, China).1 The rapid spread to more than 25 other countries 
across the world (Centers of Disease Control and Prevention, 2020) 
and the high number of contagions (over 70 000) in only 1 month 
after the first case report on December 31, 2019, is alarming for all 
the world's human populations (https://www.who.int/emerg encie 
s/disea ses/novel -coron aviru s-2019. Although the fatality rate of 
SARS-CoV-2 is around 4%, lower than previous SARS-CoV (severe 
acute respiratory syndrome coronavirus and MERS-CoV [Middle 
East respiratory syndrome coronavirus], WHO has highlighted the 
importance of strengthening collaborative efforts among scientists 
to develop effective interventions for controlling and preventing 
the epidemic).2–4 Coronaviruses belong to the family Coronaviridae 
and are characterized by a positive-sense single-stranded RNA ge-
nome that was released via the community online resource virolog-
ical.org on 10 January (Wuhan-Hu-1, GenBank accession number 
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The ongoing outbreak of the novel coronavirus (SARS-CoV-2) infection is creating 
serious challenges for health laboratories that seek to identify viral infections as early 
as possible, optimally at the earliest appearance of symptom. Indeed, there is ur-
gent need to develop and deploy robust diagnostic methodologies not only to use in 
health laboratory environments but also directly in places where humans circulate 
and spread the virus such as airports, trains, boats, and any public aggregation places. 
The success of a reliable and sensitive asymptomatic diagnosis relies on the iden-
tification and measurement of informative biomarkers from human host and virus 
in a rapid, sensitive, and inexpensive manner. The objective of this article is to de-
scribe an innovative multidisciplinary approach to develop an efficient, inexpensive, 
and easy-to-use portable instrument (bCUBE® by Hyris Ltd) that can be employed 
as a surveillance system for the emergency caused by SARS-CoV-2. A solution for 
Coronavirus testing, compliant with CDC guidelines, is scheduled to be released in 
the next weeks. In addition, we will describe a workflow and path of an integrated 
multi-omic approach that will lead to host and pathogen biomarker discovery in order 
to train the instrument to provide reliable results based on a specific biomarker's 
fingerprint of SARS-CoV-2 infection.
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MN908947). After that, four other genomes were deposited on 12 
January in the viral sequence database of the Global Initiative on 
Sharing All Influenza Data (GISAID). The genome sequence showed 
that the virus is closely related to the coronavirus causing severe 
acute respiratory syndrome (SARS), agent of the 2002/03 outbreak 
of SARS in humans. This virus family includes a large number of vi-
ruses present in rhinolophid bats in both Europe and Asia. These 
viruses are pathogen of animals such as birds and mammals. In hu-
mans, they typically induce mild respiratory infections, generally ob-
served in the common cold.
A workflow of the coronavirus primary screening has been 
shown in Figure 1. A reliable diagnosis of the viral infection is one the 
most urgent priorities for public health management of the disease 
spread. Usually in acute respiratory infection, RT-PCR is tradition-
ally employed to identify viruses in respiratory secretions. A robust 
detection technology is usually based on real-time RT-PCR because 
it is highly sensitive and specific, although it requires infrastructure, 
skilled personnel and at least 4-6 hours for analysis. Currently avail-
able techniques do not provide results before several hours or even 
days, and the tests require a well-equipped laboratory and trained 
personnel. Indeed, these methods are not efficient to rapidly screen 
a high number of individuals in places where thousands of people 
transit per hours. These methods are effective in confirming the 
infections when symptoms are already present but they are com-
pletely inefficient to identify infections at asymptomatic stage. The 
development of a means for a quick and simple detection of this 
virus in humans is a worldwide priority considering that infections 
have been observed in world areas such as Africa where the scarce 
health assistance will not be able to control the spread. Indeed, it is 
important to generate new ideas that will allow the development of 
new detection prototypes able to quickly identify infected humans 
and prevent the virus from spreading.
2  | BIOMARKER IDENTIFIC ATION
A large number of possible host-pathogen biomarkers (transcripts, 
miRNAs, proteins, metabolites) may be analyzed through different 
omic tools. Here, we propose the application of a portable instru-
ment based on the analysis of molecular responses at transcript 
level. The proposed approach consists in the adaptation of an ex-
isting infield portable technology currently used for real-time de-
tection of viral agents in plants, for detection of SARS-CoV-2 in 
confined and contaminated environments (for example, airports, 
buildings, and boats). It links translational genomics to technolo-
gies, potentially enhancing the discovery of SARS-CoV-2-specific 
biomarkers while bridging gaps in conventional human virus detec-
tion and molecular diagnostics methods. An analysis at two comple-
mentary levels (host transcriptional responses and viral nucleic acid 
presence) may allow clarification of the pathogenetic mechanisms 
of the viral agent identifying strict and complex cause-effect rela-
tionships occurring in the host-pathogen interactions. Traditional 
approaches are based on pathogen DNA/RNA and protein detec-
tion using, respectively, PCR-based or protein-based methods in 
traditional laboratory instruments. However, this kind of method 
is not useful in the quest to reduce the spread of SARS-CoV-2 in-
fections because: (a) The virus is not uniformly distributed within 
human tissues and is therefore often missed when at low titers 
undetectable with current real-time PCR technologies; (b) the virus 
has high incubation times (14-30 days) at asymptomatic conditions 
F I G U R E  1   Steps of current coronavirus primary screening
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having the capability to be highly contagious at this stage; (c) the 
analysis with traditional methods takes time for sample transport, 
extraction and analysis (16-24 hours at least) reducing the speed 
of viral spread counteracting actions; and (d) the need of skilled 
personnel to perform analysis. The proposed strategy is focused 
on the analysis of human responses that are triggered during viral 
infection with specific emphasis on the immune responses that 
are upregulated rapidly after infection and are locally at the site 
of infection (nose nostrils and also at a distance (lungs and other 
organs). Biomarkers that are associated with such responses can 
be found both locally and at certain distance from nostrils. At the 
early-stage event of the host-pathogen interaction, a “stress condi-
tion” typically occurs such as a “inflammatory response” due to the 
activation of recognition mechanisms of pathogen-associated and 
pathogen-induced virulence factors. These early asymptomatic re-
sponses are typically linked with changes in both host and the viral 
agent at transcriptional and the post-transcriptional levels with 
specific, mRNA, miRNA, non-coding RNA, proteins, and metabo-
lites activated in response to the pathogen presence.
Through the comparison of transcriptomic signatures under 
asymptomatic and symptomatic conditions, genes associated with 
the beginning of disease symptoms can be identified. The molecular 
processes precede symptom's appearance, when human host ac-
tivate more physiological responses, leading to disease-associated 
phenotypic modifications and metabolic problems linked to 
pathogen virulence factors. The human response itself may lead 
to detrimental effects, exaggerating the direct pathogen action 
or inducing mutually negative actions. Prevention of SARS-CoV-2 
disease spread may require: (a) development of portable instru-
ments for rapid, easy and reliable detection of viral infections at 
a presymptomatic stage; (b) development therapeutic methods 
for destruction of SARS-CoV-2 before irreversible negative ef-
fects on human health has occurred (these approaches may focus 
on targeting of human immune system); and (c) identification of 
pathways and bioactive compounds that can stimulate the innate 
immune responses. Indeed, the proposed approach is to identify 
and analyze biomarkers modulated in either host or pathogen at 
early stages of infection. When any eukaryotic host is subjected 
to stress, an “induced stress response” occurs similarly to the 
host “inflammatory response” to pathogen-associated and patho-
gen-induced virulence factors.5 If the induced stress response is 
enhanced, tissue injury can happen, causing to irreversible effects 
at asymptomatic stages, because it is often too late to avoid tis-
sue and organ damages once symptoms appear. During the early 
stages of this condition, the induction of immune stress-related 
genes and pathways commonly associated with pathogen infec-
tion and physiological disorders occur and these genes are typi-
cally associated with general early state of stress response. Other 
differentially regulated genes at the presymptomatic stage are 
stress specific and may work as useful biomarkers for the early 
diagnosis of the host health conditions. These responses include 
changes in the key metabolic pathways associated with key indica-
tors of early stages of infection of known pathogens. Usually, this 
stress condition usually anticipates the manifestation of symp-
toms associated with diseases. For this reason, a focus on the anal-
ysis of key genes, transcripts, proteins, metabolites, or pathways 
could be used to monitor the human health status. These induced 
biological molecules may be used as biomarkers for both stress 
identification and recovery. The identification of molecules that 
are early host responses associated in a reversible stress status 
using portable instruments is the first stage for asymptomatic di-
agnosis. The biomarker's identification needs the analysis of large 
data sets through web-based applications that queries large public 
databases of information on transcripts, proteins, or metabolites 
modulated in specific biological conditions (ie, Genevestigator).
Here, we propose the employment of an instrument that is al-
ready widely used for plant pathogens6,7 and could be easily adapted 
also for the detection of SARS-CoV-2. The idea is to use a porta-
ble DNA-based detection devices not only targeting viral RNA but 
also analyze a pool of early responsive host transcripts. This tran-
scriptional fingerprint would greatly enhance early asymptomatic 
detection of a viral such as SARS-CoV-2 having more than 14 days 
of asymptomatic stage. This complementary approach on host and 
pathogen will overcome the limits of an approach aiming at only tar-
get the pathogen DNA that is unreliable at asymptomatic stage, es-
pecially in case of pathogen with systemic diffusion such as viruses. 
A molecular analysis of early human responses may complement tra-
ditional methods based on the identification of the pathogen pres-
ence, enhancing the detection of first infections at asymptomatic 
stage. Surely, the expression analysis of a single gene of any host 
does not allow the specific diagnose of infections because there are 
no host genes strictly specific for a specific pathogen. However, a 
pool of responsive host genes might be employed as host biomark-
ers to quickly identify early alarm stress state, better than aspecific 
methods currently used such the measurement of body temperature 
for fever detection. A biomarker can be defined as a biological char-
acteristic that can be analyzed and considered as an indicator of a 
particular physiological such as pathogenic processes, or responses 
to a therapeutic intervention. In omic sciences, a “biomarker profile” 
includes a series of transcriptomic, proteomic, and/or metabolomic 
features linked with a particular stress, development of physiologi-
cal condition. Combined, these characteristics could become a bio-
marker of pathogenic condition assisting in diagnosis and therapy. A 
systems-based approach could gain insight into underlying biologi-
cal regulatory network (BRN) governing interactions between hosts 
and pathogens. Heterogeneous omic data sets could be integrated 
to define a biological regulatory network underlying early host and 
pathogen biomarkers for asymptomatic detection of the viral infec-
tions. To assist the biomarkers discovery, the vast amount of tran-
scriptomic data available in public databases in response to human 
coronaviruses will allow a deep meta-analysis using previously cus-
tomized bioinformatics pipelines Ref. [8–11]. This work consists of 
re-analyzing raw data obtained by independent experiments using a 
normalization and standardization procedure included in a bioinfor-
matics pipeline. This work will provide differentially regulated genes 
from each study finding commonalities and differences in genes, 
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genet sets, pathways, and gene/protein networks to clarify molec-
ular mechanisms in host-pathogen interactions.12
The genome sequence of SARS-CoV-2 is closely related to 
that of SARS-CoV. Like SARS-CoV and MERS-CoV, SARS-CoV-2 
belongs to the Betacoronavirus genus),4,13 having a genome size 
of ~30 kilobases, similarly with the other coronaviruses, encod-
ing for multiple structural and non-structural proteins.14,15 In ad-
dition, SARS-CoV-2 seems to have similar cell entry mechanism 
and type of human cell receptor.4,16,17 T cells respond well against 
the structural proteins that are most immunogenic compared to 
the non-structural proteins.18 Among them, the S and N proteins 
have showed to be the most dominant and long-lasting by T-cell 
responses.19 Indeed, as possible targets for pathogen nucleic acid 
detection for bCUBE® we may suggest the following: proteins in-
cluding spike (S) proteins, envelope (E) proteins, membrane (M) pro-
teins, and nucleocapsid (N) proteins. No mutation in SARS-CoV-2 
sequences (as of February 6, 2020) has been observed in com-
parison with the experimentally determined SARS-CoV-derived 
B-cell epitopes (both linear and discontinuous) implying that these 
epitopes have the potential to elicit a cross-reactive/effective re-
sponses against SARS-CoV-2).20 Indeed as host response targets, 
we may suggest to test IFNγ TNFα, IL-2, as suggested by previous 
data.18,21 Indeed, S peptides showed the highest percentages of 
IFNγ producing cells.
Proteomics may be also used to validate the discovery of tran-
scriptional markers analyzing the same infection stages considered 
at transcript level. A possible technique could be the isobaric Tags 
for Relative and Absolute Quantitation (iTRAQ), typically employed 
in quantitative proteomics using tandem mass spectrometry to an-
alyze quantitative measurements of protein amount from different 
sources in a single experiment. Briefly, once proteins are extracted 
from the same collected tissues (nostril tissues), they may be precipi-
tated using ProteoExtractTM Protein Precipitation kit (Calbiochem), 
dehydrated, resuspended, and digested with tripsin and generated 
peptides analyzed using a system composed by QExactive mass 
spectrometer, an Easy-LC and a nanospray ionization source. Data 
could be acquired using a data-dependent ms/ms method and raw 
data should be analyzed using X!Tandem, visualized using Scaffold 
Proteome software and proteins identified using Uniprot databases 
and cRAP database. The use of proteomics should enable identi-
fication not only viral proteins but also host proteins modulated 
by early infection (at the same way of transcriptomics, a comple-
ment approach host-pathogen is required). Some of the identified 
pathogen virulence proteins may be selected for further validation 
through expression in model animals to validate their virulence 
phenotype. Synthetic virulence genes should be designed to insure 
higher in vivo expression through codon's optimization (ie, using 
DNAworks software, http://mcl1.ncifc rf.gov/dnaworks). Signal pep-
tides could be analyzed by SignalP 4.0 server, and N-Glycosylation 
sites could be predicted using NetNglyc1.0 (http://www.cbs.dtu.
dk/servi ces/NetNg lyc/). This approach has been successful to de-
termine more than 4500 proteins in plants including both host and 
pathogen.7 Considering the systemic presence of SARS-CoV-2, the 
identification of specific genes from peripheral blood and different 
tissues would be very helpful to discover tissue-specific host bio-
markers. The viral infection is typically perceived by the host before 
that the viral nucleic acid can be detected by traditional methods 
such as quantitative real-time PCR.
3  | PORTABLE INSTRUMENT FOR 
CORONAVIRUS INFIELD DETEC TION
Here, we propose the use of the portable device such as bCUBE®2.0 
(developed by Hyris Ltd).
The device is a miniaturized device that is able to perform both 
temperature cycles and isothermal analysis, enabling a wide array of 
nucleic acid detection methods such as qPCR and isothermal ampli-
fications (Figure 2), with a power consumption of maximum 60 W. 
The instrument runs custom thermal cycling protocols and performs 
real-time PCR analyses. The instrument, sized 100 × 100 × 120 mm 
with a weight of 1.15 kg, is certified to both European and North 
American standards. Thanks to a live sync to a central database, it 
can be monitored and controlled remotely from any device or in mo-
bile with a Smartphone. The analysis can be performed using custom-
ized cartridges to analyze in multiplex way up to 16 or 36 samples of 
10-25 μL in one run, on two detection channels (FAM/HEX).
The key features of this system are the following:
• viral detection in 1.5 hours using RT-PCR
• automatic result interpretation
• high resolution melting and isothermal amplification options
• wireless or wired connectivity.
The bCUBE® 2.0 can be controlled by the Hyris bAPP, a mul-
tiplatform GUI that works on smartphones, tablets, laptops, and 
PCs with typical operating systems (Figure 3). Key features are the 
following:
• manage one or multiple bCUBEs on the field or remotely
• manage and configure access privileges in your network
• run custom protocols for RD or use public “Global Recipes” for 
validated applications
• design and perform analysis and tests using either real-time PCR 
or isothermal protocols
• use the data for internal QA, or to generate and receive in real 
time third party Certificates
• aggregate and perform in depth statistical, process and quality 
controls leveraging also on correlated data like timestamps and 
geolocalization of samples.
This miniaturized instrument has been recently proposed 
for highly threatening pathogen outbreak in agriculture such as 
Xylella fastidiosa in olive.6 The instrument has typically been 
used for the detection of plant viral infections directly in field. 
The novelty is the possibility to use the detection principles 
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and methodologies from the infield detection of plant virus in 
crops to quick and portable detection of a dangerous viral agent 
in humans such as SARS-CoV-2. The instrument analyzes mRNA 
in <2 hours directly in the field, without the need of laboratory 
infrastructures, through the performance of a qRT-PCR analysis. 
Gene expression could be conducted collecting samples from 
human nostrils with tools such as cotton swabs. Confirmation 
may be performed blood samples. RNA may be extracted from 
these collection instruments with a quick procedure using simpli-
fied extraction procedures.
The typical workflow for the use of the instrument for pathogen 
detection is shown in Figure 4. Results may be provided in approx-
imately 2 hours. At the moment, the developed software and hard-
ware are used to target the pathogen DNA, but a next step could 
F I G U R E  2   Components of Hyris platform: bCUBE®, bAPP, bKit, and starter kit
F I G U R E  3   Additional details of the components of the portable system
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be the analysis of host Xf-regulated genes discovered by meta-anal-
ysis works. Implementation and validation tests of the results ob-
tained directly by the portable device could be conducted analyzing 
the same tissues with traditional laboratory equipment. This work 
would verify the consistency of the field results delivered by the 
instrument.
4  | CONCLUSIONS
The proposed instrument fits well when a quick, easy, reliable and in-
house early detection (and confirmation) is required to rapidly decon-
taminate environments and initiate quarantine of infected individuals. 
The workflow for a secondary coronavirus screening using bCUBE® is 
F I G U R E  4   Typical workflow for the use of bCUBE® for detection of pathogens from DANN extraction to results readout
F I G U R E  5   Possible workflow of Coronavirus secondary screening using bCUBE® portable instrument
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shown in Figure 5. The system is able to detect not only viruses, but 
also specific bacteria, proteins, and DNA molecules, an increased or 
reduced concentration of which in a person's saliva, blood and other 
tissues (ie, nostrils) provide the diagnosis of the SARS-CoV-2 infections. 
The most important aspect of this tool is the extreme ease of use and 
the automatic interpretation of the results. The app has an intuitive in-
terface and can guide the operator through every step of the setup and 
analysis. Initiation in the analysis is simple and the automatic result in-
terpretation engine can assist the operator in determining the outcome. 
The supplied power source works at both 110 V and 220 V, and the 
power cord can be easily interchanged with the one compatible with 
the standard of your destination country. Real-time and remote control 
of the bCUBEs is allowed thanks to the connection to Hyris bDATA® 
service. The instrument is well suitable to work on boats and other 
quarantine environments for the possibility to have results in short 
time. It also fits well in the airports after a quick scan of other symp-
toms (ie, fever) in order to confirm the presence of the viral infections.
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